Free Trial
OTCMKTS:CLPBY

Coloplast A/S Q1 2025 Earnings Results & Report

Coloplast A/S logo
$7.04 +0.16 (+2.33%)
As of 03:57 PM Eastern

Coloplast A/S missed analyst earnings expectations in its Q1 2025 results, released February 4, 2025. The company reported EPS of $0.07 versus the $0.08 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Coloplast A/S EPS Results

Actual EPS
$0.07
Consensus EPS
$0.08
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Coloplast A/S Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Coloplast A/S Q1 2025 Earnings FAQ

Coloplast A/S (OTCMKTS:CLPBY) reported earnings of $0.07 per share for Q1 2025, missing the consensus estimate of $0.08. The report was announced on Tuesday, February 4, 2025.

Coloplast A/S' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Coloplast A/S on the company's earnings history page.

Coloplast A/S Earnings Headlines

Coloplast A/S (OTCMKTS:CLPBY) Stock Price Up 3.9% - Should You Buy?
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
CLPBY Share News Today
Coloplast: Went 'BUY' A Bit Early
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) is a Denmark-based medical technology company that develops and markets products and services for people with intimate and chronic healthcare needs. Its principal business areas include ostomy care, continence care, wound and skin care, and interventional urology.

The company’s product portfolio includes ostomy bags and accessories, skin-protection products, intermittent catheters, bowel-management systems, and devices used in urological procedures. Recognized brands include SenSura and Brava in ostomy care, SpeediCath in continence care, and Peristeen for bowel management.

Coloplast traces its origins to the 1950s, when nurse Elise Sørensen developed an adhesive ostomy bag to help her sister manage an ileostomy. The company was established in 1957 by Aage Louis-Hansen and his wife, Johanne Louis-Hansen. Headquartered in Humlebæk, Denmark, Coloplast serves healthcare professionals and patients in markets across Europe, North America, and other international regions. Kristian Villumsen has served as the company’s president and chief executive officer.

View Coloplast A/S Profile